Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
6.87
-0.10 (-1.43%)
At close: Mar 4, 2026, 4:00 PM EST
6.91
+0.04 (0.58%)
After-hours: Mar 4, 2026, 7:56 PM EST

Telix Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts with 12-month price forecasts for Telix Pharmaceuticals stock have an average target of 21.13, with a low estimate of 20 and a high estimate of 22.5. The average target predicts an increase of 207.57% from the current stock price of 6.87.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $20 $21.13 $22 $22.5
Change +191.12% +207.57% +220.23% +227.51%

Analyst Ratings

The average analyst rating for Telix Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Sep '25Oct '25Nov '25Dec '25Jan '26Feb '26
Strong Buy 333333
Buy 111111
Hold 000000
Sell 000000
Strong Sell 000000
Total 444444

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Citigroup
Citigroup
Strong Buy
Maintains
$22$23
Strong Buy Maintains $22$23 +227.51% Feb 24, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$20
Strong Buy Reiterates $20 +191.12% Jan 21, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$20
Strong Buy Reiterates $20 +191.12% Dec 22, 2025
UBS
UBS
Strong Buy
Maintains
$23$20
Strong Buy Maintains $23$20 +191.12% Sep 23, 2025
Citigroup
Citigroup
Strong Buy
Initiates
$22
Strong Buy Initiates $22 +220.23% Sep 18, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.